CORE Trial - Institute of Cancer Research

A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases

The term oligometastases describes the concept of an intermediary state where cancer exists as a limited number of metastases before cells acquire the ability to metastasise more widely. It is hypothesised that successful eradication of disease at oligometastatic stage may improve survival outcomes and even cure for a select few.

The CORE trial investigates if adding SBRT to standard therapy improves survival outcomes, focusing on common primary tumour sites where oligometastatic disease is encountered: non‐small cell lung cancer (NSCLC), breast and prostate.

CORE is a phase II/III multi‐centre, non‐blinded, randomised controlled trial comparing standard of care (SOC) with or without SBRT for extra‐cranial metastases. The primary endpoint is Progression Free Survival (PFS).

The phase II component of CORE aims to demonstrate:

  • Feasibility of randomised recruitment
  • Deliverability of the study in an international multi‐centre setting
  • SBRT activity based on PFS across the three tumour types.

If all three aims are achieved additional funding will be sought to roll the study into parallel tumour‐site specific phase III trials.

View Inclusion/Exclusion criteria

View CORE Trial Key data slide 

For more information contact Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), London, UK.

Join Lung Cancer Nursing UK

Be a member of a dynamic and cohesive forum of lung cancer nurse specialists (LCNS) working throughout the UK. Membership costs just £30 per year and is open to any specialist nurse who spends more than 50% of their working week or clinical activities in caring for patients with lung cancer.

Join Now

Register for PRON 2020

The PRON Programme, is a unique 2 day residential workshop for nurses interested in increasing their skills, knowledge and confidence in clinical research related to lung cancer.

Find out more